Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Istaroxime - Windtree Therapeutics

Drug Profile

Istaroxime - Windtree Therapeutics

Alternative Names: Debio 0614; PST 2744; ST 2744

Latest Information Update: 20 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer Windtree Therapeutics
  • Class Amines; Androstanols; Cardiotonics; Heart failure therapies; Ketosteroids; Oximes; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Decompensated heart failure

Most Recent Events

  • 25 Oct 2019 Windtree Therapeutics plans a phase II trial for Acute heart failure in the second half of 2020
  • 25 Oct 2019 Windtree Therapeutics plans a clinical trial study for Cardiogenic shock in the first half of 2020
  • 13 Aug 2019 Istaroxime receives Fast track status from the US FDA for Acute heart failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top